Trial Profile
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Registrational
- Sponsors Celator Pharmaceuticals; Jazz Pharmaceuticals Inc
- 12 Dec 2023 Results of a PopPKPD model analysis using data from three clinical studies: NCT00389428, NCT02238925 and NCT01696084 presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 19 Dec 2018 Results of the population pharmacokinetics analysis based on pooled data from Study 101, 206 and 301 (n=195) published in the Journal of Clinical Pharmacology
- 23 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.